ArticlePhysics and imaging in radiation oncology2024
Machine learning automated treatment planning for online magnetic resonance guided adaptive radiotherapy of prostate cancer.
Article in Physics and imaging in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Online adaptive radiotherapy: International strategies for AI-enabled workflow efficiency and radiation therapist-led delivery for sustainable practice.Technical innovations & patient support in radiation oncology · 2026Article
- Development of an artificial intelligence driven dose prediction pipeline for online adaptive magnetic resonance-guided radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Beyond auto-segmentation: the case for planning and dosimetry AI in head and neck radiation oncology.BMJ oncology · 2026Review
- AI-driven precision diagnosis and treatment of prostate cancer: a narrative review.Frontiers in oncology · 2026Review
- Artificial Intelligence Across the Prostate Cancer Pathway: Screening, Imaging, Pathology, and Biomarkers.Cureus · 2025Review
- Comparison of online adaptation strategies for magnetic resonance guided prostate radiation therapy.Physics and imaging in radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: No best practices currently exist for achieving high quality radiation therapy (RT) treatment plan adaptation during magnetic resonance (MR) guided RT of prostate cancer. This study validates the use of machine learning (ML) automated RT treatment plan adaptation and benchmarks it against current clinical RT plan adaptation methods. Materials and methods: We trained an atlas-based ML automated treatment planning model using reference MR RT treatment plans (42.7 Gy in 7 fractions) from 46 patients with prostate cancer previously treated at our institution. For a held-out test set of 38 patients, retrospectively generated ML RT plans were compared to clinical human-generated adaptive RT plans for all 266 fractions. Differences in dose-volume metrics and clinical objective pass rates were evaluated using Wilcoxon tests (p < 0.05) and Exact McNemar tests (p < 0.05), respectively. Results: Compared to clinical RT plans, ML RT plans significantly increased sparing and objective pass rates of the rectum, bladder, and left femur. The mean ± standard deviation of rectum D20 and D50 in ML RT plans were 2.5 ± 2.2 Gy and 1.6 ± 1.3 Gy lower than clinical RT plans, respectively, with 14 % higher pass rates; bladder D40 was 4.6 ± 2.9 Gy lower with a 20 % higher pass rate; and the left femur D5 was 0.8 ± 1.8 Gy lower with a 7 % higher pass rate. Conclusions: ML automated RT treatment plan adaptation increases robustness to interfractional anatomical changes compared to current clinical adaptive RT practices by increasing compliance to treatment objectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.